Neuronetics, Inc. (STIM): Entry into a Material Definitive Agreement

Neuronetics, Inc. (STIM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. As previously disclosed, on July 25, 2024, Neuronetics, Inc. (the “Company”) entered into a Credit Agreement and Guaranty (as amended, the “Existing Credit Agreement”) with Perceptive Credit Holdings IV, LP (“Perceptive”), as

Event · Debt financing
Instrument
Amendment No. 6 to Credit Agreement and Guaranty
Amount
$15,000,000
Lender
Perceptive Credit Holdings IV, LP

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 10, 2026, 9:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 9:11 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$STIM
Neutral
high confidence
Mentioned
$STIM
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$STIMNeutralMed
01

Why it matters

First disclosure of covenant modifications; investors will reassess credit risk.

02

Market read

A modest corporate financing update that could affect short‑term price dynamics.

03

What to watch

Potential impact of covenant changes on future financing costs and credit rating.

Relevance 6/10Novelty 6/10Timing: after‑hours filing today

Background

The amendment updates the existing credit facility originally signed in 2024.

Company-level read

Ticker impact

$STIMNeutralHigh confidence
Context

Neuronetics filed an 8‑K reporting Amendment No. 6 to its credit agreement, modifying revenue covenants and adding a $15 M optional prepayment clause.

Expected impact

likely slight pressure as investors assess covenant changes

Evidence & confidence

The filing is the first public disclosure of the amendment; market will price in potential covenant strain and the $15 M prepayment option.

Market effects

May signal tighter credit conditions for small‑cap med‑tech firms.

Limited to U.S. listed biotech/med‑tech segment.

Low

Counterpoint

If the optional prepayment is exercised, cash inflow could boost the balance sheet and support the stock.

Key entities

  • Neuronetics, Inc.

    Medical device company filing the amendment.

  • Perceptive Credit Holdings IV, LP

    Administrative agent and majority lender on the credit agreement.

Related articles

$STIMHigh

Why is Neuronetics stock tumbling today?

Neuronetics Inc's stock fell 11.4% in pre-market trading after pricing a $30M share offering at a discount. The company aims to use proceeds to address going concern risks and meet a $15M loan prepayment deadline by November 30, 2026. Despite Q3 revenue growth, these factors drove the decline, with no broader market impact.

$STIMHigh

Neuronetics stock tumbles 10% on stock offering launch

Neuronetics Inc (STIM) shares dropped 10% in after-hours trading after announcing a public stock offering and a credit agreement amendment. The company aims to sell shares with a 30-day option for underwriters to buy 15% more. The amendment reduces revenue covenants if certain conditions are met by November 30, 2026, addressing going concern risks. William Blair, BTIG, and Canaccord Genuity are managing the offering.

$STIMHigh

Neuronetics Inc (STIM) (Q3 2026) Earnings Call Highlights: Revenue Jumps

Neuronetics Inc (STIM) reported Q3 2026 revenue of $42M, up 12.5% YoY, driven by Greenbrook's 20.1% growth. Gross margin expanded to 52.2%, and operating expenses decreased 12.6%, leading to positive adjusted EBITDA of $1.9M. NeuroStar revenue grew only 1.8% YoY, with session revenue declining. Cash balance decreased to $27.9M. Management expects full-year 2026 cash flow to be negative $10M to $12M.

$STIMMed

Neuronetics Q3 Earnings Call Highlights

Neuronetics reported Q3 revenue growth driven by record system sales, with capital and lease units making up over half of sales. The company expects lower treatment-session revenue as it shifts focus to larger customers. Neuronetics anticipates higher growth in 2027 and beyond. It also submitted a 510(k) application for an accelerated TMS protocol and cited a study showing treatment gaps do not reduce effectiveness.